Sirturo

Johnson & Johnson Offers Global Access by Not Enforcing Sirturo’s Tuberculosis Drug Secondary Patents

3 October 2023

Anika Sharma

Johnson & Johnson has taken significant steps to improve access to its multidrug-resistant tuberculosis (MDR-TB) medication, Sirturo (bedaquiline), in low- ...

Johnson & Johnson, tuberculosis, patent rights, generic competition, Sirturo, bedaquiline

J&J cuts TB drug price by 55% after giving up patent rights

31 August 2023

Anika Sharma

Just seven weeks after announcing its willingness to permit generic competition for the drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in ...